Is Cumberland Pharmaceuticals Stock a Good Investment?
Cumberland Pharmaceuticals Investment Advice | CPIX |
- Examine Cumberland Pharmaceuticals' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Cumberland Pharmaceuticals' leadership team and their track record. Good management can help Cumberland Pharmaceuticals navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Pharmaceuticals space and any emerging trends that could impact Cumberland Pharmaceuticals' business and its evolving consumer preferences.
- Compare Cumberland Pharmaceuticals' performance and market position to its competitors. Analyze how Cumberland Pharmaceuticals is positioned in terms of product offerings, innovation, and market share.
- Check if Cumberland Pharmaceuticals pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Cumberland Pharmaceuticals' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Cumberland Pharmaceuticals stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Cumberland Pharmaceuticals is a good investment.
Sell | Buy |
Strong Sell
Market Performance | OK | Details | |
Volatility | Dangerous | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Average | Details | |
Economic Sensitivity | Almost mirrors the market | Details | |
Investor Sentiment | Interested | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Poor | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Cumberland Pharmaceuticals Stock
Researching Cumberland Pharmaceuticals' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 44.0% of the company shares are held by company insiders. The book value of Cumberland Pharmaceuticals was currently reported as 1.64. The company recorded a loss per share of 0.46. Cumberland Pharmaceuticals last dividend was issued on the 29th of October 2010. The entity had 2:1 split on the 6th of July 2007.
To determine if Cumberland Pharmaceuticals is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Cumberland Pharmaceuticals' research are outlined below:
| Cumberland Pharmaceuticals is way too risky over 90 days horizon | |
| Cumberland Pharmaceuticals appears to be risky and price may revert if volatility continues | |
| Cumberland Pharmaceuticals has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 37.87 M. Net Loss for the year was (6.44 T) with profit before overhead, payroll, taxes, and interest of 31.28 M. | |
| Cumberland Pharmaceuticals currently holds about 18.22 M in cash with (612.19 B) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.24. | |
| Cumberland Pharmaceuticals has a poor financial position based on the latest SEC disclosures | |
| Roughly 44.0% of the company shares are held by company insiders | |
| Latest headline from finance.yahoo.com: FIGHT DMD Trial Results Selected for Late-Breaking Presentation at MDA Clinical Scientific Conference |
Cumberland Pharmaceuticals uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Cumberland Pharmaceuticals. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Cumberland Pharmaceuticals' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 5th of March 2024 Upcoming Quarterly Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View |
Earnings surprises can significantly impact Cumberland Pharmaceuticals' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Cumberland Pharmaceuticals' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2020-05-20 | 2020-03-31 | 0.02 | 0.01 | -0.01 | 50 | ||
2012-11-01 | 2012-09-30 | 0.09 | 0.1 | 0.01 | 11 | ||
2012-02-29 | 2011-12-31 | 0.05 | 0.04 | -0.01 | 20 | ||
2011-03-08 | 2010-12-31 | 0.03 | 0.04 | 0.01 | 33 | ||
2021-03-09 | 2020-12-31 | -0.01 | 0.01 | 0.02 | 200 | ||
2013-02-28 | 2012-12-31 | 0.14 | 0.12 | -0.02 | 14 | ||
2012-08-02 | 2012-06-30 | 0.07 | 0.09 | 0.02 | 28 | ||
2010-08-16 | 2010-06-30 | 0.03 | 0.01 | -0.02 | 66 |
Cumberland Pharmaceuticals Target Price Consensus
Cumberland target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Cumberland Pharmaceuticals' target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| One | Strong Buy |
Most Cumberland analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Cumberland stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Cumberland Pharmaceuticals, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationCumberland Pharmaceuticals Target Price Projection
Cumberland Pharmaceuticals' current and average target prices are 4.13 and 8.50, respectively. The current price of Cumberland Pharmaceuticals is the price at which Cumberland Pharmaceuticals is currently trading. On the other hand, Cumberland Pharmaceuticals' target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
Cumberland Pharmaceuticals Market Quote on 27th of March 2025
Target Price
Analyst Consensus On Cumberland Pharmaceuticals Target Price
Cumberland Pharmaceuticals Analyst Ratings
Cumberland Pharmaceuticals' analyst stock recommendations are determined by taking an average estimate of all analysts we track and classifying them as Strong Buy, Buy, Hold, Strong Sell, or Sell. Ratings generally communicate what analysts sense about Cumberland Pharmaceuticals stock, and they use a lot of effort and time to analyze it and arrive at a rating. That suggests that analyst recommendations are the outcome of an objective and thorough examination of Cumberland Pharmaceuticals' financials, market performance, and future outlook by experienced professionals. Cumberland Pharmaceuticals' historical ratings below, therefore, can serve as a valuable tool for investors.Know Cumberland Pharmaceuticals' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Cumberland Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Cumberland Pharmaceuticals backward and forwards among themselves. Cumberland Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Cumberland Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Ubs Group Ag | 2024-12-31 | 8.2 K | Morgan Stanley - Brokerage Accounts | 2024-12-31 | 2.7 K | Tower Research Capital Llc | 2024-12-31 | 2.2 K | Capital Advisors, Ltd. Llc | 2024-12-31 | 437 | Wells Fargo & Co | 2024-12-31 | 250 | Bank Of America Corp | 2024-12-31 | 65.0 | Jpmorgan Chase & Co | 2024-12-31 | 19.0 | Huntington National Bank | 2024-12-31 | 1.0 | Schonfeld Strategic Advisors Llc | 2024-12-31 | 0.0 | Renaissance Technologies Corp | 2024-12-31 | 507.2 K | Vanguard Group Inc | 2024-12-31 | 374.3 K |
Cumberland Pharmaceuticals' market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 60.48 M.Market Cap |
|
Cumberland Pharmaceuticals' profitablity analysis
| Last Reported | Projected for Next Year |
Determining Cumberland Pharmaceuticals' profitability involves analyzing its financial statements and using various financial metrics to determine if Cumberland Pharmaceuticals is a good buy. For example, gross profit margin measures Cumberland Pharmaceuticals' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Cumberland Pharmaceuticals' profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Cumberland Pharmaceuticals' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Cumberland Pharmaceuticals. Check Cumberland Pharmaceuticals' Beneish M Score to see the likelihood of Cumberland Pharmaceuticals' management manipulating its earnings.
Evaluate Cumberland Pharmaceuticals' management efficiency
Cumberland Pharmaceuticals has return on total asset (ROA) of (0.0511) % which means that it has lost $0.0511 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2488) %, meaning that it created substantial loss on money invested by shareholders. Cumberland Pharmaceuticals' management efficiency ratios could be used to measure how well Cumberland Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is expected to grow at the current pace this year. Return On Capital Employed is expected to grow at the current pace this year. At this time, Cumberland Pharmaceuticals' Total Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 41.1 T in 2025, whereas Other Assets are likely to drop slightly above 7.4 M in 2025.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 1.6 M | 1.7 M | |
| Tangible Book Value Per Share | 260.2 K | 273.2 K | |
| Enterprise Value Over EBITDA | -405.5 K | -385.2 K | |
| Enterprise Value Multiple | -405.5 K | -385.2 K | |
| Enterprise Value | 2.6 T | 2.7 T |
The operational strategies employed by Cumberland Pharmaceuticals management play a crucial role in its market positioning. Assessing these strategies alongside financial data helps us evaluate the stock's investment potential.
Beta (0.18) |
Basic technical analysis of Cumberland Stock
As of the 27th of March, Cumberland Pharmaceuticals shows the Downside Deviation of 6.71, mean deviation of 7.42, and Risk Adjusted Performance of 0.1139. Cumberland Pharmaceuticals technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.Cumberland Pharmaceuticals' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Cumberland Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Cumberland Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Cumberland Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Cumberland Pharmaceuticals' Outstanding Corporate Bonds
Cumberland Pharmaceuticals issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Cumberland Pharmaceuticals uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Cumberland bonds can be classified according to their maturity, which is the date when Cumberland Pharmaceuticals has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
Understand Cumberland Pharmaceuticals' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Cumberland Pharmaceuticals' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.1139 | |||
| Market Risk Adjusted Performance | 1.35 | |||
| Mean Deviation | 7.42 | |||
| Semi Deviation | 5.92 | |||
| Downside Deviation | 6.71 | |||
| Coefficient Of Variation | 808.18 | |||
| Standard Deviation | 12.84 | |||
| Variance | 164.94 | |||
| Information Ratio | 0.1231 | |||
| Jensen Alpha | 1.58 | |||
| Total Risk Alpha | 1.62 | |||
| Sortino Ratio | 0.2357 | |||
| Treynor Ratio | 1.34 | |||
| Maximum Drawdown | 98.19 | |||
| Value At Risk | (10.76) | |||
| Potential Upside | 17.7 | |||
| Downside Variance | 45.01 | |||
| Semi Variance | 35.08 | |||
| Expected Short fall | (10.88) | |||
| Skewness | 3.44 | |||
| Kurtosis | 17.92 |
| Risk Adjusted Performance | 0.1139 | |||
| Market Risk Adjusted Performance | 1.35 | |||
| Mean Deviation | 7.42 | |||
| Semi Deviation | 5.92 | |||
| Downside Deviation | 6.71 | |||
| Coefficient Of Variation | 808.18 | |||
| Standard Deviation | 12.84 | |||
| Variance | 164.94 | |||
| Information Ratio | 0.1231 | |||
| Jensen Alpha | 1.58 | |||
| Total Risk Alpha | 1.62 | |||
| Sortino Ratio | 0.2357 | |||
| Treynor Ratio | 1.34 | |||
| Maximum Drawdown | 98.19 | |||
| Value At Risk | (10.76) | |||
| Potential Upside | 17.7 | |||
| Downside Variance | 45.01 | |||
| Semi Variance | 35.08 | |||
| Expected Short fall | (10.88) | |||
| Skewness | 3.44 | |||
| Kurtosis | 17.92 |
Consider Cumberland Pharmaceuticals' intraday indicators
Cumberland Pharmaceuticals intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Cumberland Pharmaceuticals stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Cumberland Pharmaceuticals Corporate Filings
8K | 19th of March 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 18th of March 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
| 10th of March 2025 Other Reports | ViewVerify | |
10K | 7th of March 2025 Annual report required by the U.S. Securities and Exchange Commission (SEC) of a company financial performance | ViewVerify |
Cumberland Stock media impact
Far too much social signal, news, headlines, and media speculation about Cumberland Pharmaceuticals that are available to investors today. That information is available publicly through Cumberland media outlets and privately through word of mouth or via Cumberland internal channels. However, regardless of the origin, that massive amount of Cumberland data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Cumberland Pharmaceuticals news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Cumberland Pharmaceuticals relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Cumberland Pharmaceuticals' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Cumberland Pharmaceuticals alpha.
Cumberland Pharmaceuticals Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Cumberland Pharmaceuticals can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Cumberland Pharmaceuticals Corporate Management
| James Herman | Chief Compliance Officer and VP of National Accounts | Profile | |
| John Hamm | Chief Officer | Profile | |
| Christophe Bitterman | Vice Marketing | Profile | |
| Todd Anthony | Vice Development | Profile | |
| Adam Mostafa | Managing Relations | Profile | |
| Erin Gull | Senior Associate | Profile |
Additional Tools for Cumberland Stock Analysis
When running Cumberland Pharmaceuticals' price analysis, check to measure Cumberland Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cumberland Pharmaceuticals is operating at the current time. Most of Cumberland Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Cumberland Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cumberland Pharmaceuticals' price. Additionally, you may evaluate how the addition of Cumberland Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.